[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560883":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":59,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":26,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The study group","EXPERIMENTAL","Patients in the study group will receive MRI-guided adaptive stereotactic radiotherapy (without PTV expansion margin). The total dose will be 30Gy\u002F5 fractions, administered once daily. The MRI-linac is used for the delivery of radiotherapy.",[13],"Radiation: MRI-guided adaptive SRT",{"label":15,"type":16,"description":17,"interventionNames":18},"The control group","ACTIVE_COMPARATOR","Patients in the study group will receive conventional standard stereotactic radiotherapy (with PTV expansion margin). The total dose will be 30Gy\u002F5 fractions, administered once daily. The conventional linac is used for the delivery of radiotherapy.",[19],"Radiation: Conventional SRT",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","MRI-guided adaptive SRT","MRI-guided online adaptive SRT (without PTV expansion margin). The total dose will be 30Gy\u002F5 fractions, administered once daily. MRI will be acquired.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Conventional SRT","Conventional SRT (with PTV expansion margin). The total dose will be 30Gy\u002F5 fractions, administered once daily. CBCT will be acquired.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Hui Liu","CONTACT","13661150862","liuhuisysucc@126.com",{"name":38,"role":34,"phone":35,"phoneExt":26,"email":39},"DaQuan Wang","wangdq@sysucc.org.cn",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Sun yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":57,"role":34,"phone":58,"phoneExt":26,"email":36},"Hui Liu, MD","+86-020-87343031",{"type":60,"investigatorFullName":33,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Professor","100560883","phase-2-elimination-of-ptv-margins-based-on-mri-guided-adaptive-stereotactic-radiotherapy-for-non-small-cell-lung-cancer-with-brain-metastasis-100560883",false,"NCT06582940","Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis","Inclusion Criteria:\n\n* Aged 18-75 years\n* Histologically or cytologically confirmed non-small cell lung cancer\n* 1-10 metastases on contrast-enhanced MRI\n* Radiotherapy for extracranial lesions is permitted\n* Tyrosine kinase inhibitors (TKI) are permitted in patients with progression of\n* intracranial metastases during previous TKI therapy\n* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Normal function of organs and bone marrow within 14 days: Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; absolute neutrophil count≥ 500 cells\u002Fmm3; creatinine clearance rate(CCR) ≥45 mL\u002Fmin; Platelet count≥50,000 cells\u002Fmm3; international normalized ratio(INR) ≤1.5#Prothrombin Time (PT)≤ 1.5 × ULN\n* Informed-consent\n\nExclusion Criteria:\n\n* Small cell carcinoma of lung\n* Intracranial metastases needed surgical decompression\n* Patients with contraindications for MRI\n* Previous radiotherapy or excision for intracranial metastases\n* Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months\n* Uncontrolled hypertension (systolic \\> 150mmHg and\u002For diastolic \\> 100mmHg)\n* Major surgery within 28 days or minor surgery or needle biopsy within 48 hours\n* Urine protein 3-4+, or 24h urine protein quantitative \\>1g\n* Severe uncontrolled disease\n* Uncontrollable seizure or psychotic patients without self-control ability\n* Women in pregnancy, lactation period\n* Other not suitable conditions determined by the investigators","ALL","18 Years","75 Years",{"count":72,"type":73},168,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.",[79,80,81],"MRI-guided Adaptive Radiotherapy","Non-small Cell Lung Cancer","Brain Metastasis",[83,84,85],"MRI-guided radiotherapy","lung cancer","brain metastasis","2025-11-14",{"date":88,"type":89},"2025-11-17","ACTUAL",{"date":91,"type":89},"2024-03-01",{"date":93,"type":73},"2026-03-01",{"name":5,"class":6},1]